Agilent Technologies (A)

Agilent’s products help customers identify, measure and analyse chemical and biological substances. Its portfolio includes chromatography systems, mass spectrometry instruments, spectroscopy tools, pathology and genomics products, laboratory automation, reagents, columns and related software. These technologies are used by pharmaceutical companies in drug research and quality control, by diagnostic and clinical labs, by chemical and advanced materials manufacturers, and by organisations working in food safety, environmental testing, forensics, academia and government research.

A key feature of Agilent’s business is the recurring demand attached to its installed base of instruments. Laboratories that use its systems often continue to buy consumables, replacement parts, service contracts and workflow support over many years. This gives the company exposure not only to new equipment cycles, but also to more stable revenue streams linked to routine testing and regulated laboratory operations.

Agilent operates internationally, with important markets in the United States, China, Europe and other major research and industrial regions. Its performance is influenced by pharmaceutical R&D spending, bioprocessing and diagnostics demand, industrial production trends, government research budgets and capital spending by laboratories. For investors, Agilent represents a large-cap life science tools and diagnostics supplier with diversified end markets, a broad technology base and strong links to the long-term growth of analytical testing.